Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0837 feasibility study in atrial fibrillation patients unable or unwilling to take vitamin K antagonists
2007-001723-36Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of atecegatran metoxil in Atrial fibrillation (AFib) (2 arms), sponsored by AstraZeneca. Primary endpoint: Feasibility of conducting the study. Started May 2007; status: completed.
02
Drugs
atecegatran metoxil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2007-001723-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001723-36.